Comparison
Semaglutid vs. Thymalin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
910463-68-2
63958-90-7
Molecular weight
4113.6 g/mol
1000 g/mol
Half-life
165 h
0.5 h
Sequence
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linkerno data
Mechanism of action
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Thymalin
Thymalin is a complex of multiple polypeptides extracted from bovine or calf thymus. Postulated mechanisms include modulation of T-lymphocyte maturation, influence on interleukin profiles and stimulation of cellular immune response. Being a multi-component preparation, individual mechanisms are difficult to disentangle. Khavinson and colleagues from St Petersburg have described the mechanism over decades in Russian publications.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
4
of which in humans
3
2
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
5
1